‘What’s Really Important Is, What Are We Doing Next?’: Sandoz On Biosimilar Ambitions

Adalimumab, Denosumab, Natalizumab, And Aflibercept All Under Discussion

 
• By Dean Rudge
  
Sandoz logo on building
• Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products